RxDoctor Payments Data

Solomon Hamburg, MD

Hematology & Oncology · Encino, CANPI 1801892302

Payments from drug & device makers

$123,040in general payments, 2019–2025

Across 131 payments — averaging $939.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$122K
  • Beigene USA, Inc.$352
  • Pharmaessentia USA Corporation$269
  • Karyopharm Therapeutics Inc.$145
  • Pfizer$45
  • Array Biopharma Inc$44
  • plus $103 from 4 others

What the payments were for

  • Consulting fees$26,53822%
  • Speaking & faculty fees$82,64669%
  • Travel & lodging$8,2197%
  • Food & beverage$2,3352%
  • Education$450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$123,040 in reported general payments places this provider in the 70th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California

Medicare billing

Part B allowed, 2024
$2,574,087
Medicare patients
556
Services billed
112,732

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate40$695,045
PomalystPomalidomide17$421,479
BrukinsaZanubrutinib34$418,444
CalquenceAcalabrutinib Maleate19$293,029
RevlimidLenalidomide17$262,736
TasignaNilotinib Hcl12$106,053
XareltoRivaroxaban14$13,364
EliquisApixaban22$13,153
Enoxaparin Sodium16$3,789
Fentanyl15$989
Anastrozole34$641
Hydroxyurea24$404
Levothyroxine Sodium26$376
Escitalopram Oxalate17$301
Zolpidem Tartrate19$296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$122,082$695,04540 claims
Beigene USA, Inc.Brukinsa$352$418,44434 claims
NovartisTasigna$23$106,05312 claims
PfizerEliquis$45$13,15322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,363 hematology & oncology providers in California.

Other hematology & oncology in Encino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →